登录查看更多内容

Latest Release of CFDA! The Upgraded and Implemented Data Protection System to Help Chinese Innovative Drugs

Julia Zhang

B2B Editor at PharmaSources.com

发布日期: 2018年5月15日

By Xiaoyaowan

Click to read the full article:Latest Release of CFDA! The Upgraded and Implemented Data Protection System to Help Chinese Innovative Drugs

The Office of CFDA has started to seek public opinions on Implementation Measures for Drug Trial Data Protection (Interim) on April 26, which is introduced to improve and implement the pharmaceutical product trial data protection system, promote pharmaceutical product innovation, improve accessibility of Chinese innovative drugs, and meet clinical drug use demand.

Data protection system—the intellectual property protection system in parallel with the patent systemAs an intellectual property protection system in parallel with the pharmaceutical product patent system, the data protection system will not extend the term of pharmaceutical product patent protection but can provide the most basic market protection for pharmaceutical products without patent protection or with insufficient patent production, especially for the newly developed innovative drugs, with the ultimate aim to stimulate the innovation activities of pharmaceutical enterprises.

Click to read the full article:Latest Release of CFDA! The Upgraded and Implemented Data Protection System to Help Chinese Innovative Drugs

要查看或添加评论，请登录

Julia Zhang的更多文章

Animal Studies for Predicting Drug Toxicity - Is it Time to Re-Evaluate the Benefits?

2020年9月2日

Animal Studies for Predicting Drug Toxicity - Is it Time to Re-Evaluate the Benefits?

By Neeta Ratanghayra The use of animal testing has significant benefits in medical research; however, increased costs…
Hope for Africa in fight against RSV and new vaccine shows promise

2020年9月1日

Hope for Africa in fight against RSV and new vaccine shows promise

By Shem Oirere Africa’s hope of further reducing the neonatal deaths estimated at 28 per 1,000 live births, has…
FDA Generally Recognized As Safe (GRAS) 101

2020年8月31日

FDA Generally Recognized As Safe (GRAS) 101

By Dr. Lin Zhang Generally recognized as safe (GRAS) is the FDA designation that a chemical or substance added to food…
Pharma Business Benefit from the Shift of Sales and Marketing to a More Digitally-driven Approach

2020年8月28日

Pharma Business Benefit from the Shift of Sales and Marketing to a More Digitally-driven Approach

By Dr. Sarah Harding The ongoing COVID-19 pandemic is continuing to have a significant impact on the way we do business.
Overseas Marketing of Fruquintinib Accelerated as It Receives the FDA’s Fast Track Designation

2020年8月4日

Overseas Marketing of Fruquintinib Accelerated as It Receives the FDA’s Fast Track Designation

By Xiaoyaowan Hutchison MediPharma’s targeted anticancer drug: fruquintinib has recently received the Fast Track…
Pharma and Health from Ingredients to Pills: Cancer Therapeutics Today

2020年8月3日

Pharma and Health from Ingredients to Pills: Cancer Therapeutics Today

By Dr. Lin Zhang Treatment of oncologic patients has progressed greatly in the last few years with the development of…
Powder Flow: Limitations of Mathematically Derived Parameters from Shear Cell Testing

2020年8月3日

Powder Flow: Limitations of Mathematically Derived Parameters from Shear Cell Testing

By Tim Freeman Shear Cell testing was originally designed to determine the incipient flow of continuous, cohesive…
Turbulent Patterns of DPP-4 Inhibitor Hypoglycemics: First Generic of Linagliptin Approved and a New Manufacturer Approved to Market Vildagliptin

2020年7月28日

Turbulent Patterns of DPP-4 Inhibitor Hypoglycemics: First Generic of Linagliptin Approved and a New Manufacturer Approved to Market Vildagliptin

By Miling Guangdong HEC Pharmaceutical’s Class 4 generic drug: Linagliptin Tablets and Nanjing Sanhome Pharmaceutical’s…
Investment Potential in Africa’s Pharmaceutical Market

2020年7月22日

Investment Potential in Africa’s Pharmaceutical Market

By Shem Oirere The Covid-19 pandemic outbreak has increased Africa’s disease burden on one hand while opening up…
Busy Month of Approvals: A Review of Oncology Drugs Approved in May in China and Abroad

2020年7月3日

Busy Month of Approvals: A Review of Oncology Drugs Approved in May in China and Abroad

By Xiaobin The first half of 2020 will pass soon. Although foreign countries are still under the shadow of the COVID-19…

See all articles

Latest Release of CFDA! The Upgraded and Implemented Data Protection System to Help Chinese Innovative Drugs

Julia Zhang

B2B Editor at PharmaSources.com

Julia Zhang的更多文章

社区洞察

其他会员也浏览了

?? Building a Competitive & Innovative Pharmaceutical Ecosystem for the EU ??

"Improving access to medicines and promoting pharmaceutical innovation" from EU Parliament released 2 days ago

The injection consistency evaluation may be comprehensively implemented as the NMPA takes frequent actions

The Mutual Recognition Agreement Rolls Along – But Where is Germany? By Mark I. Schwartz, Director, Hyman, Phelps & McNamara

Yay! Our reimbursement guide is now in its seventh edition

ePharmalink News

New academic study proposes changes to the Early Access pathway in Japan

New GMP Implementing Act published

The Effect of the U.S. and EU Mutual Recognition Agreement on Trade

Extrapolation of Indications in Authorization of Biosimilar Products

Julia Zhang的更多文章

Animal Studies for Predicting Drug Toxicity - Is it Time to Re-Evaluate the Benefits?

Hope for Africa in fight against RSV and new vaccine shows promise

FDA Generally Recognized As Safe (GRAS) 101

Pharma Business Benefit from the Shift of Sales and Marketing to a More Digitally-driven Approach

Overseas Marketing of Fruquintinib Accelerated as It Receives the FDA’s Fast Track Designation

Pharma and Health from Ingredients to Pills: Cancer Therapeutics Today

Powder Flow: Limitations of Mathematically Derived Parameters from Shear Cell Testing

Turbulent Patterns of DPP-4 Inhibitor Hypoglycemics: First Generic of Linagliptin Approved and a New Manufacturer Approved to Market Vildagliptin

Investment Potential in Africa’s Pharmaceutical Market

Busy Month of Approvals: A Review of Oncology Drugs Approved in May in China and Abroad

社区洞察

其他会员也浏览了

?? Building a Competitive & Innovative Pharmaceutical Ecosystem for the EU ??

"Improving access to medicines and promoting pharmaceutical innovation" from EU Parliament released 2 days ago

The injection consistency evaluation may be comprehensively implemented as the NMPA takes frequent actions

The Mutual Recognition Agreement Rolls Along – But Where is Germany? By Mark I. Schwartz, Director, Hyman, Phelps & McNamara

Yay! Our reimbursement guide is now in its seventh edition

ePharmalink News

New academic study proposes changes to the Early Access pathway in Japan

New GMP Implementing Act published

The Effect of the U.S. and EU Mutual Recognition Agreement on Trade

Extrapolation of Indications in Authorization of Biosimilar Products